Extracorporeal Photopheresis in Sezary Syndrome

RecruitingOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Sezary Syndrome
Interventions
DEVICE

Extracorporeal photopheresis (ECP)

Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.

DRUG

Methoxsalen Injection

Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.

Trial Locations (1)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Oleg E. Akilov, MD, PhD

OTHER

NCT05157581 - Extracorporeal Photopheresis in Sezary Syndrome | Biotech Hunter | Biotech Hunter